Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Glaucoma, Open-Angle
Ocular Hypertension

Interventions

DRUG: AGN-210669 ophthalmic solution, 0.1%
DRUG: AGN-210669 ophthalmic solution, 0.075%
DRUG: AGN-210669 ophthalmic solution, 0.05%
DRUG: bimatoprost ophthalmic solution 0.03%

Sponsor

Allergan